Role of Glycosuria in SGLT2 Inhibitor-Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial

Overview

Journal Diabetes

Specialty Endocrinology

Date 2023 Nov 8

PMID 37939214

Authors

Ele Ferrannini

Anna Solini

Simona Baldi

Tiziana Scozzaro

David Polidori

Andrea Natali

Michael K Hansen

Affiliations

Soon will be listed here.

Abstract

Article Highlights:

Citing Articles

Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetes.

Ferrannini E, Baldi S, Scozzaro M, Ferrannini G, Hansen M JCI Insight. 2024; 9(24).

PMID: 39704168 PMC: 11665565. DOI: 10.1172/jci.insight.180637.

Integrating the new pharmacological standard of care with traditional nutritional interventions in non-dialysis CKD.

De Nicola L, Cupisti A, DAlessandro C, Gesualdo L, Santoro D, Bellizzi V J Nephrol. 2024; 38(1):61-73.

PMID: 39508986 DOI: 10.1007/s40620-024-02135-y.

Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes.

Mori K, Inoue T, Machiba Y, Uedono H, Nakatani S, Ishikawa M Front Endocrinol (Lausanne). 2024; 15:1451671.

PMID: 39280006 PMC: 11393780. DOI: 10.3389/fendo.2024.1451671.

References

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T . Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124(2):499-508. PMC: 3904627. DOI: 10.1172/JCI72227. View

Sawami K, Tanaka A, Node K . Letter by Sawami et al Regarding Article, "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)". Circulation. 2023; 147(6):e73-e74. DOI: 10.1161/CIRCULATIONAHA.122.062333. View

Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A . Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. J Clin Endocrinol Metab. 2020; 105(4). DOI: 10.1210/clinem/dgaa057. View

Gullaksen S, Vernstrom L, Sorensen S, Ringgaard S, Laustsen C, Funck K . Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia. 2023; 66(5):813-825. DOI: 10.1007/s00125-023-05876-w. View

Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J . Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022; 388(2):117-127. PMC: 7614055. DOI: 10.1056/NEJMoa2204233. View

Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan D . Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24):2295-2306. DOI: 10.1056/NEJMoa1811744. View

Rohlfing C, Wiedmeyer H, Little R, England J, Tennill A, Goldstein D . Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002; 25(2):275-8. DOI: 10.2337/diacare.25.2.275. View

10.

Ferrannini E, Solini A . SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012; 8(8):495-502. DOI: 10.1038/nrendo.2011.243. View

11.

Biancalana E, Rossi C, Raggi F, Distaso M, Trico D, Baldi S . Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects. J Clin Endocrinol Metab. 2023; 108(8):e567-e573. PMC: 10348461. DOI: 10.1210/clinem/dgad088. View

12.

Watson P, Watson I, Batt R . Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980; 33(1):27-39. DOI: 10.1093/ajcn/33.1.27. View

13.

van Bommel E, Muskiet M, van Baar M, Tonneijck L, Smits M, Emanuel A . The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2019; 97(1):202-212. DOI: 10.1016/j.kint.2019.09.013. View

14.

Vaduganathan M, Docherty K, Claggett B, Jhund P, de Boer R, Hernandez A . SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400(10354):757-767. DOI: 10.1016/S0140-6736(22)01429-5. View

15.

Ferrannini E, Baldi S, Scozzaro T, Tsimihodimos V, Tesfaye F, Shaw W . Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). Diabetes Care. 2022; 45(8):1893-1899. DOI: 10.2337/dc21-2398. View

16.

Cherney D, Perkins B, Soleymanlou N, Maione M, Lai V, Lee A . Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2013; 129(5):587-97. DOI: 10.1161/CIRCULATIONAHA.113.005081. View

17.

Wright E . SGLT2 Inhibitors: Physiology and Pharmacology. Kidney360. 2022; 2(12):2027-2037. PMC: 8986039. DOI: 10.34067/KID.0002772021. View

18.

Li J, Neal B, Perkovic V, de Zeeuw D, Neuen B, Arnott C . Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 2020; 98(3):769-777. DOI: 10.1016/j.kint.2020.04.051. View

19.

. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400(10365):1788-1801. PMC: 7613836. DOI: 10.1016/S0140-6736(22)02074-8. View

20.

Packer M . Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes. Diabetes Obes Metab. 2022; 25(5):1143-1146. DOI: 10.1111/dom.14963. View